David Ricks

David Ricks, CEO of Eli Lilly and a leader steering GLP-1 drug development, discusses the science behind incretin drugs and how weight-loss effects were discovered. He explains why these medicines affect appetite, inflammation, and behavior. They cover business impacts on Lilly, R&D strategies, next-gen drug and delivery plans, public distrust of pharma, and AI’s role in drug discovery.

David Ricks, CEO of Eli Lilly, leads the pharmaceutical giant in innovative ventures, particularly with groundbreaking weight-loss drugs showing promise for various health issues. He discusses the surprising benefits of diabetes medications in combating obesity and their implications for chronic diseases. Ricks reveals how AI is revolutionizing drug development, allowing companies to cut timelines dramatically. He emphasizes the importance of curiosity-driven leadership and open communication in fostering a collaborative workplace culture.

David Ricks, Chair and CEO of Eli Lilly, discusses the groundbreaking advances in weight-reducing drugs that extend their benefits beyond initial intentions, like treating addiction and Alzheimer's. He highlights how Eli Lilly has halved drug development timelines through innovative approaches and AI. Ricks also navigates the challenges of drug pricing ethics in different markets, emphasizing the balance between patient access and business sustainability. This conversation reveals the exciting future of medicine and its transformative potential.

David Ricks, the CEO of Eli Lilly and Company, joins the conversation to share insights on revolutionizing obesity therapies. He emphasizes the significance of their groundbreaking oral GLP-1s, designed to make treatment more accessible. Ricks discusses the ambitious $50 billion investment in manufacturing to support their expansion and innovative collaborations with NVIDIA to enhance drug discovery. The discussion also touches on the broader therapeutic potential of incretins, showcasing their impact beyond weight loss.

Brian Niccol, CEO of Starbucks, discusses the company's impressive turnaround strategy, including their successful Green Apron service and expansion plans in China. David Ricks, CEO of Eli Lilly, shares insights into the strong performance of their weight-loss drug Mounjaro and hints at the potential impacts of an upcoming oral pill. Both leaders explore consumer trends and the competitive landscape in their respective industries, offering fascinating glimpses into the future of food and health.

Steve Liesman, senior economics reporter tracking jobs and labor trends. David Ricks, CEO of Eli Lilly, on pricing and growth for diabetes and weight-loss drugs. They discuss midday market drops, AI-driven selloffs in software, chip demand and ADP job data. Conversation also covers pricing moves and strong results from Lilly.

David Ricks, CEO of Eli Lilly, on pricing and rising demand for diabetes and weight-loss drugs. Mark Short, former Pence chief of staff, on geopolitics and gold’s market impact. Steve Liesman, senior economics reporter, on ADP job data, manufacturing and sector shifts. Multiple short takes on markets, jobs and commodities in rapid-fire analysis.

David Ricks, Global CEO of Eli Lilly, shares insights on tackling chronic diseases in India with the launch of Manjaro for obesity and diabetes. He discusses the delicate balance of pricing strategies that ensure accessibility while remaining profitable. Ricks also emphasizes the power of strategic partnerships in enhancing healthcare, from local businesses to tech innovations. He sheds light on the transformative role of biotechnology in health solutions and the challenges posed by political and regulatory landscapes within the pharmaceutical industry.

David Ricks, the Chairman & CEO of Eli Lilly, shares insights on the company's strategic decision to expand US manufacturing, emphasizing its impact on the pharmaceutical landscape. Carl Eschenbach, CEO of Workday, highlights a strong quarterly performance while discussing the surging demand for AI solutions in the workforce. The conversation also touches on significant market shifts, including Tesla's declining valuation and potential tariff impacts on copper, setting a dynamic backdrop for economic growth and corporate strategies.

David Ricks, CEO of Eli Lilly and Company, shares insights on the promising landscape for the company’s weight loss drugs. He discusses healthcare payment complexities and the shift in perception of obesity as a disease. The conversation also touches on the repercussions of inflation data on the market and Elon Musk's potential acquisition of TikTok, exploring the tech landscape's evolution. Amidst regulatory challenges, Ricks highlights the innovative strategies driving pharmaceutical growth, making for an engaging and informative discussion.